Growth
Conditions
Brief summary
The primary objective of the clinical trial is to compare growth in infants (expressed as weight gain in g/day) consuming a new extensively hydrolyzed formula (EHF) to infants consuming a commercially available EHF.
Interventions
New hydrolyzed infant formula.
Commercially available infant formula.
Sponsors
Study design
Eligibility
Inclusion criteria
* Healthy newborn singleton infant * Full-term (\>= 37 weeks gestation) * Birth weight between \>= 2500 and \< =4500 g * 14 ± 3 days of age on enrollment * Infant's mother has elected not to breastfeed * baby has been exclusively formula fed a minimum of 3 days prior to enrollment * Study explained and written information provided with Parent/Caregiver * Informed consent signed (parent/legal representative)
Exclusion criteria
* Congenital illness or malformation affecting infant feeding and/or growth * Suspected or known allergy to cow's milk protein * Significant pre-natal and/or post-natal disease * Any readmission to hospital (except for hyperbilirubinemia) prior to enrollment * Infant has received oral or IV antibiotic therapy in the 10 days prior to enrollment * Infant receiving prescription medication (with exception of topical antibiotics and/or treatment for thrush) or frequent use of over the counter medications except vitamin and mineral supplements * Infant has received probiotics in the seven days prior to enrollment * Infant currently participating in another clinical study * Infant's family who in the Investigator's assessment cannot be expected to comply with the protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Weight Gain | 4 Months | Mean weight gain (g/day) from enrollment to 4 months of age. |
Countries
United States